Tech Support


This line is for technical support.
For General Enquiries please click General Contact


POSTER: The FATZO Mouse – A Translatable Model for GLP-1 Agonist Screening

Semaglutide in the FATZO Mouse: A New Mouse Model of Type II Diabetes

Richard G Peterson, Charles V Jackson, Karen Zimmerman, Tamer Coskun*, and Paul Emmerson*
*Eli Lilly and Co, Indianapolis, IN

FATZO Mouse Poster

Glucagon-like Peptide-1 (GLP-1) receptor agonists, e.g. semaglutide, improve glucose homeostasis and reduce body weight in humans and in mouse models of Type II diabetes.

CrownBio has developed the MS-NASH (formerly called FATZO) Type II diabetes model, selectively bred for obesity, insulin resistance, and hyperglycemia, whilst maintaining an intact leptin pathway and fed normal chow. The MS-NASH (FATZO) mouse has now been studied to demonstrate its value in the preclinical screening of GLP-1 receptor agonists.

Read this Poster to Discover:

  • That semaglutide demonstrates anti-diabetic and anti-obesity efficacy in the MS-NASH (FATZO) mouse

  • The dose dependent decreases in both food consumption and body weight observed, as well as insulin resistance improvement

  • How the benefits of semaglutide in the MS-NASH (FATZO) mouse may provide a model highly translatable to human diabetes and obesity

Download the Poster Now!

Download This Poster Now

Your privacy is important to us.
We'll never share your information.